Pharmacologic Inhibition of TRPA1 Counteract CS Tear Gas Agent-induced Cutaneous Injuries

Satyanarayana Achanta¹*, Narendranath Reddy Chintagari²§, Shrilatha Balakrishna²ѱ, Boyi Liu¹†, and Sven-Eric Jordt¹,³,⁴*

¹Center for Translational Pain Medicine, Department of Anesthesiology, Duke University School of Medicine, Durham, NC-27710, USA

²Department of Pharmacology, Yale University School of Medicine, New Haven, CT – 06520, USA

³Department of Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, NC-27710, USA

⁴Integrated Toxicology and Environmental Health Program (ITEHP), Nicholas School of the Environment, Duke University, Durham, NC-27710, USA

Current affiliations:

§US Food and Drug Administration (FDA), Bethesda, MD, USA

ѱOffice of Animal Research Support, Yale University, 25 Science Park, New Haven, CT, USA

†Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Hangzhou, 310053, China
Running title:

TRPA1 inhibitors ameliorate tear gas agent-induced skin injuries

*Corresponding authors:
Email: satya.achanta@duke.edu (S Achanta)
E-mail address: sven.jordt@duke.edu (S.-E. Jordt)
Department of Anesthesiology, Duke University School of Medicine, Box 3094, MS27, Durham, NC 27710-3094, USA

Number of text pages: 33
Number of Tables: 0
Number of Figures: 6
Number of references: 68
Total word count of the Abstract: 246
Total word count of the Introduction: 878
Total word count of the Discussion: 1698
List of abbreviations, acronyms, and symbols

A96 (A967079)

AITC (allyl isothiocyanate)

CBRNE (chemical, biological, radiological, nuclear, or explosive)

CS (2-Chlorobenzalmalononitrile)

CXCL2/MIP-2 (chemokine (C-X-C motif) ligand 2/macrophage inflammatory protein 2)

DMEM (Dulbecco’s Modified Eagle Medium)

DMSO (dimethyl sulfoxide)

EC\textsubscript{50} (half maximal effective concentration)

ELISA (enzyme-linked immunosorbent assay)

F\textsubscript{0} (basal fluorescence)

F\textsubscript{max} (maximum fluorescence)

HC (HC-030031)

HEK293T (human embryonic kidney 293T)

HRW (Human Rights Watch)

hTRPA1 (human transient receptor potential ion channel ankyrin repeat 1)

i.p (intraperitoneal);

i.v (intravenous);

IC\textsubscript{50} (The half-maximal inhibitory concentration)

IL-1\beta (Interleukin-1 beta)

KC/CXCL1 (keratinocyte chemoattractant)/(chemokine (C-X-C motif) ligand 1)

MC (methylcellulose)

MMP-9 (matrix metalloproteinase-9)

mTRPA1 (mouse transient receptor potential ion channel ankyrin repeat 1)

RCA (riot control agent)
RNS (reactive nitrogen species)

ROS (reactive oxygen species)

RSDL (reactive skin decontamination lotion)

TRPA1 (transient receptor potential ion channel ankyrin 1)

$$\Delta F = \text{change in fluorescence} = F_{\text{max}} \text{ (maximum fluorescence)} - F_0 \text{ (basal fluorescence)}$$
Abstract

Deployment of the tear gas agent 2-chlorobenzalmalnonitrile (CS) for riot control has significantly increased in recent years. The effects of CS have been believed to be transient and benign. However, CS induces severe pain, blepharospasm, lachrymation, airway obstruction, and skin blisters. Frequent injuries and hospitalizations have been reported following exposure. We have identified the sensory neuronal ion channel, transient receptor potential ankyrin 1 (TRPA1), as a key CS target resulting in acute irritation and pain, and also as a mediator of neurogenic inflammation. Here, we examined the effects of pharmacologic TRPA1 inhibition on CS-induced cutaneous injury. We modeled CS-induced cutaneous injury by applying 10 µL CS agent (200 mM in dimethyl sulfoxide, DMSO) to each side of the right ears of 8-9 week-old C57BL/6 male mice, whereas left ears were treated with solvent only (DMSO). The TRPA1 inhibitor HC-030031 or A-967079 was administered post-CS exposure. CS exposure induced strong tissue swelling, plasma extravasation, and a dramatic increase in inflammatory cytokine levels in the mouse ear skin. We also showed that the effects of CS were not transient, but caused persistent skin injuries. These injury parameters were reduced with TRPA1 inhibitor treatment. Further, we tested the pharmacologic activity of advanced TRPA1 antagonists in vitro. Our findings showed that TRPA1 is a crucial mediator of CS-induced nociception and tissue injury, and that TRPA1 inhibitors are effective countermeasures that reduce key injury parameters when administered post-exposure. Additional therapeutic efficacy studies with advanced TRPA1 antagonists and decontamination strategies are warranted.

Key words: TRPA1; TRPA1 antagonists; HC-030031; A-967079; CS tear gas (2-chlorobenzalmalnonitrile); riot control agents, skin injuries
Significance statement:

CS tear gas agent has been deployed as a crowd dispersion chemical agent in recent times. Exposure to CS tear gas agents has been believed to cause transient acute toxic effects that are minimal at most. Here, we found that CS tear gas exposure causes both acute and persistent skin injuries and that treatment with transient receptor potential ion channel ankyrin 1 (TRPA1) antagonists ameliorated skin injuries.
Visual abstract
Introduction

Deployment of the tear gas agent CS (2-chlorobenzalmalononitrile, C₁₀H₅ClN₂, CAS: 2698-41-1), for riot control has significantly increased in recent years (Olajos and Salem, 2001; Blain, 2003; Bessac et al., 2009; Bessac and Jordt, 2010; Schep et al., 2013; Torgrimson-Ojerio et al., 2021). CS tear gas has been commonly used by police forces as a riot control agent (RCA) to disperse crowds and subdue individuals. While CS tear gas was banned as a chemical weapon in warfare, its use in domestic riot control is allowed, but has been highly controversial. Some countries, including the United States, train their newly recruited military and armed forces with tear gas agents under different simulative conditions as part of their chemical, biological, radiological, nuclear, and high yield explosives (CBRNE) training (Hout et al., 2011; Martin, 2022). Some casualties have been reported during such CBRNE training sessions (Hout et al., 2011). Despite its description as a safe riot control agent, CS tear gas agent is not without harmful side effects. The effects of CS tear gas have been believed to be transient. Reported deaths are few while injuries are many (Rappert, 2003; Watson and Rycroft, 2005; Agrawal et al., 2009; Lam et al., 2020). Several countries do not have proper regulations on the use of tear gas agents for incapacitating riots. In the last couple of years, the indiscriminate use of tear gas as a riot control agent in the United States, Middle Eastern countries, and many other countries around the world has led to worldwide criticism from several corners, including the Human Rights Watch (HRW) (1970; Aktan, 2013). Some countries have banned the use of CS tear gas agents due to their perceived effects on the reproductive system (Hayman, 2011). Of note, the Biological and Chemical Weapons Convention, signed by almost all countries, had banned the use of tear gas on the war front, but its use in domestic riot control is allowed (Davenport, 2020).
Tear gas agents are well known to cause several effects including severe pain, blepharospasm, lachrymation, and airway obstruction (Olajos and Salem, 2001; Varma and Holt, 2001; Smith and Greaves, 2002; Karaman et al., 2009; Shambhu and Kurtis, 2011; Schep et al., 2013). Eyes, respiratory system, and skin are commonly exposed (Agrawal et al., 2009). Ocular and respiratory irritation occurs within a few seconds. The toxic effects of CS tear gas agents on the cutaneous system vary. Common cutaneous outcomes are irritation, bulla formation, burns, subcutaneous edema, and contact dermatitis (Southward, 2001; Watson and Rycroft, 2005; Schep et al., 2013; Arbak et al., 2014). Some studies have reported contact dermatitis with repeated exposure to CS tear gas agent (Kain et al., 2010; Shambhu and Kurtis, 2011; Bhargava et al., 2012; Lam et al., 2020). Several short-term and long-term effects of CS tear gas agents have been reported (Karagama et al., 2003; Karaman et al., 2009; Kain et al., 2010; Arbak et al., 2014). Some suggestions in the public domain for decontamination and treatment of tear gas agents include water, milk, Vaseline, vinegar, lemon juice, or antacids. However, these remedies and decontamination procedures are not scientifically proven. Decontamination of contaminated surfaces is also difficult as the CS tear gas agent is almost insoluble in water and only slightly soluble in ethyl alcohol and carbon tetrachloride. The actual concentrations of incapacitating agents to which civilians and law enforcement authorities are exposed vary considerably, which complicates the assessment of consequences and further treatment. Although some therapeutics have been tested for CS tear agent-induced injuries, symptomatic treatment remains the most common approach to treatment (Jones, 1996; Viala et al., 2005; Luka et al., 2007; Carron and Yersin, 2009; Schep et al., 2013). Thus, to the best of our knowledge, no specific antidote for tear gas-induced cutaneous injuries is available (Schep et al., 2013). Indeed, the best prophylactic
option for preventing injuries from CS tear gas exposure is running away or removing the individual from the source.

Although several studies have been performed to elucidate the mechanism of action of tear gas agents and their treatment, there remains a knowledge gap in the standards of care for tear gas agent-induced casualties based on mechanistic studies. The seminal work of Bessac, BF et al, 2008 and other studies showed that transient receptor potential ion channel ankyrin repeat 1 (TRPA1) mediates CS tear gas-induced inflammation in \emph{in vitro} studies (Bessac and Jordt, 2008; Brone et al., 2008; Bessac and Jordt, 2010). TRPA1 is a chemoreceptor for environmental irritants and inflammatory agents (Bautista et al., 2013; Julius, 2013). TRPA1 channels are activated by a variety of stimuli (either chemical or environmental) including, but not limited to, aldehydes (acrolein and allyl isothiocyanate (AITC)), terpenes (thymol and carvacrol), irritants, voltage, cold, stretch, and flufermic acid. Endogenous products of reactive oxygen species (ROS) and reactive nitrogen species (RNS) such as 4-hydroxynonal, activate TRPA1 channels (Bautista et al., 2013; Julius, 2013; Achanta and Jordt, 2020). However, no \emph{in vivo} studies have demonstrated therapeutic effects of TRPA1 antagonists on CS tear gas-induced cutaneous inflammation.

The objective of this study is to confirm that TRPA1 is the mediator of CS tear gas agent-induced inflammation, using \emph{in vivo} studies, and to test the therapeutic potential of TRPA1 antagonists such as HC-030031 and A-967079 in mouse ear models of CS tear gas agent-induced cutaneous injury.
Materials and methods

Chemicals, animals, and drugs

C56BL/6 male 8-9 week-old mice were purchased from Charles River Laboratories, Wilmington, MA. Mice were given at least 1 week to acclimate before initiating studies, and access to mouse chow and water *ad libitum*. All animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Yale University (New Haven, CT) and Duke University (Durham, NC).

The TRPA1 antagonist HC-030031 ((2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide) was a generous gift from Hydra Biosciences (Cambridge, MA, USA) and the TRPA1 antagonist A-967079 ((1E,3E)-1-(4-Fluorophenyl)-2-methyl-1-pentene-3-one oxime) was custom-synthesized by Medchem101 (Conshohocken, PA, USA). AMG0902 was purchased from R&D Systems (Minneapolis, MN). GDC-0334 ((2S,4R,5S)-4-fluoro-1-((4-fluorophenyl)sulfonyl)-5-methyl-N-((5-(trifluoromethyl)-2-(2-(trifluoromethyl)pyrimidin-5-yl)pyridin-4-yl)methyl)pyrrolidine-2-carboxamide) was a generous gift from Genentech, San Francisco, CA. Methyl cellulose was purchased from Fluka (Buchs, Switzerland, Methocell MC, medium viscosity, 1200-1800 mPa.s.). CS tear gas was purchased from Combi-Blocks (San Diego, CA, USA). All other chemicals and reagents used were obtained from Fisher Scientific, Sigma Aldrich, or other scientific suppliers.

Mouse models of CS tear gas agent-induced skin injury

In the acute mouse model, the right ears of mice were exposed to 20 µL of 200 mM CS tear gas agent (10 µL on each surface of the ear) whereas the left ears were exposed to an equal volume of dimethyl sulfoxide (DMSO, a vehicle for CS tear gas agent). At 0.5 and 4 hours after
CS tear gas exposure, mice were administered a TRPA1 antagonist, HC-030031 (HC) or A-967079 (A96), or 0.5% methylcellulose (MC, vehicle for TRPA1 antagonists) intraperitoneally (i.p), at a dose of 200 mg/kg and 100 mg/kg body weight, respectively. Figure 1A shows the study paradigm.

In chronic (extended observation) studies for up to 5 days post-CS tear gas agent exposure, right ears were exposed to CS tear gas agent, and left ears were exposed to DMSO, similar to the acute mouse model. Mice were administered HC (200 mg/kg, i.p), A96 (200 mg/kg i.p), or vehicle at 30 minutes post-CS exposure. Additional doses of HC (100 mg/kg, i.p), A96 (100 mg/kg, i.p), or vehicle were given at 4 hours, 24 hours, and 48 hours post-CS exposure. Figure 4A shows the study paradigm.

Visualizing extravasation of inflammatory exudate

To visualize the extravasation of inflammatory exudate into surrounding tissues, and monitor the healing process in CS tear gas-exposed ears, we injected IRDye 800CW intravenously (i.v) at 4 hours post-CS exposure. Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) cocktail injected (i.p). Anesthetized mice were placed in supine positioning and scanned at 6 hours after CS tear gas exposure using Li-Cor Odyssey CLX® fitted with Mouse-Pod® (Li-Cor, Nebraska, USA) set at 37°C temperature. We used the following settings for scanning of mice: channels - 700/800; scan resolution - 42 µm; intensities - 1 for both channels; data analysis - small animal; scan quality - medium (increasing the scan quality increases the time of scanning); focal offset - 1 mm. The manufacturer's Small Animal Image Analysis Suite was used to evaluate the data.

*Ear punch biopsy sample collection, pro-inflammatory cytokines, and histopathology analysis*
Mice were euthanized at 6.5 hours after CS tear gas exposure. Tissue edema was estimated by measuring ear thicknesses with electronic calipers (Mitutoyo QUICKmini, Japan) and ear punch biopsy weights (4-mm biopsy punch needle, Japan), as described previously (Achanta et al., 2018).

Ear punch biopsy samples were homogenized in 50 mM Tris-base and 150 mM NaCl, with EDTA-free protease inhibitor, and 0.5% Triton-X, using a Bullet Blender and Zirconium Oxide Beads (Next Advance, Troy, NY, USA). Homogenization was performed for at least 20 minutes at 10-speed setting on the Next Advance bullet blender (Troy, NY, USA). After that, samples were centrifuged at 10,000g for 10 minutes at 4°C. Homogenized supernatant samples were used to measure inflammatory cytokine markers, including interleukin-1 beta (IL-1β), keratinocyte chemoattractant/chemokine (C-K-X motif) ligand 1 (KC/CXCL1), chemokine (CXC) ligand 2/macrophage inflammatory protein 2 (CXCL2/MIP-2), and matrix metalloproteinase 9 (MMP9). R&D Systems cytokine kits (Minneapolis, MN, USA) or a high throughput multiplex cytokine assay system (MILLIPLEX MAP Mouse Cytokine/Chemokine Magnetic Bead Panel, Millipore, MO, USA) was used for cytokine quantification. All samples were evaluated at least in duplicate on the Infinite M200 Pro (Tecan, Germany) or Bio-Plex 200 system (Bio-Rad, Hercules, CA, USA) systems. The concentrations of cytokines were measured using a 5-parameter logistic regression analysis or a standard curve, in accordance with the manufacturer's instructions. Cytokine concentrations that fell outside of the standard curve range were not included. The concentrations of protein in homogenate samples were determined using Pierce BCA protein assay (Thermo Scientific, Rockford, IL, USA).

Histopathology
For histopathology evaluation, 4-mm circular ear punch biopsy samples were fixed in 10% formaldehyde, embedded in paraffin, sectioned at a 5-µm thickness, and stained with hematoxylin and eosin (H&E), as per standard protocols. AxioVision Rel. 4.7 software (Zeiss, Munich, Germany) was used to examine the images, which were captured using a Zeiss Axio Imager Z1 microscope. The evaluation of cutaneous histopathology was conducted in accordance with the standards provided by Silny et al., 2005 (Silny et al., 2005). Primarily, we assessed histopathological features such as edematous swelling, integrity of the epidermis, epidermal thickening, and infiltration of leucocytes.

Decontamination of CS tear gas skin exposure with water washing

Currently, neither antidotes nor decontamination strategies are available to protect against injury from CS tear gas exposure. To assess the decontamination efficacy of water washing after skin exposure to CS tear gas agent, 30 minutes after CS exposure, we washed both surfaces of ears three times with fresh cotton applicators moistened with water (Figure S3).

In vitro cell culture and pharmacologic screening of advanced TRPA1 antagonists

Cell culture and in vitro pharmacologic screening of advanced TRPA1 antagonists for inhibition of CS tear gas-induced calcium (Ca^{2+}) influx was performed as described previously (Caceres et al., 2017). Briefly, HEK293T cells were cultured and plated on poly-D-lysine-coated 100-mm tissue culture plastic dishes in DMEM and supplemented with 10% FBS, 100 units/mL penicillin, and 0.1 mg/mL streptomycin. At 60%–70% confluency, using Fugene 6 transfection reagent and Opti-MEM, cells were transiently transfected with mouse or human TRPA1 plasmid DNA, according to the manufacturer’s protocols, for 16–24 h. Cells were then re-suspended and seeded at a density of 50,000 cells per well (100 μL per well) onto poly-D-lysine-coated 96-well
plates. After 24 hours, the intracellular influx of calcium ([Ca\(^{2+}\)\(_i\)]) was determined by loading Calcium 6, a no-wash fluorescent indicator, for ~1.5 hours (Molecular Devices, San Jose, CA, USA). Fluorescence was measured in the FlexStation at 37°C (excitation: 485 nm, emission: 525 nm at every 1.8 seconds) (FlexStation III, Molecular Devices, San Jose, CA). After recording baseline fluorescence, fluorescence was monitored for response to agonist (CS tear gas agent) for a total of 60 seconds. To determine the pharmacologic effects of TRPA1 antagonists, TRPA1-transfected HEK293T cells were pretreated with advanced TRPA1 antagonists such as A967079, AMG0902, or GDC0334, and then exposed to CS tear gas agent (agonist, a concentration near EC\(_{50}\)). The change in fluorescence was determined (\(\Delta F = F_{\text{max}} - F_0\), where \(F_{\text{max}}\) is the maximum fluorescence and \(F_0\) is the baseline fluorescence measured in each well). The EC\(_{50}\) and IC\(_{50}\) values were determined by non-linear regression analysis with a 4-parameter logistic equation (GraphPad Prism version 10.0.3 for Windows, San Diego, CA, USA).

Data Analysis and Statistics

GraphPad Prism (version 10.0.3 for Windows, San Diego, CA) was used to analyze the data. One-way ANOVA with Tukey's post hoc multiple comparison test, or the two- or one-tailed Student's t-test was used to assess for statistical differences. Outliers were removed by Dixon's Q-test. Statistical significance was denoted by *\(p<0.05\), ** \(p < 0.01\), *** \(p <0.001\), or ns = non-significant. Some of the illustrations have been created using BioRender.com.
Results

Significant acute edema and inflammation were observed after cutaneous CS tear gas agent exposure

A CS tear gas agent-induced mouse ear model of inflammation was established (Figure 1A, Figures S1 and S2). After cutaneous exposure to the CS tear gas agent, skin edema (determined by ear thickness (61% increase over control) and ear punch biopsy weights (55% increase over control)) was observed (Figure 1B-C) and levels of pro-inflammatory cytokines, such as MMP9 (59% increase over control), KC/CXCL1 (97% increase over control), and IL-1β (82% increase over control), were elevated (Figure 1B-F). Using in vivo imaging, we found significant vascular leakage (36% increase in the intensity of IRDye 800 CW dye fluorescence over control) into the subcutaneous tissue after CS tear gas agent exposure (Figure 2A). Cutaneous edema was the most prominent feature in histopathology profiles after CS tear gas exposure (Figure 3B).

CS tear gas-induced acute inflammation was reduced after treatment with TRPA1 antagonists

HC-030031, a first-generation TRPA1 inhibitor, and A967079, a second-generation TRPA1 inhibitor, were tested for mitigating CS tear gas-induced skin injuries. After treatment with these TRPA1 antagonists, edema measured by ear thickness (HC, 119% reduction and A96, 53% reduction compared to the vehicle-treated group) and ear punch biopsy weights (HC, 72% reduction and A96, 41% reduction compared to the vehicle-treated group) was significantly reduced (p<0.05) (Figures 1B-C). Treatment with HC or A96 mitigated a profound inflammatory response measured by pro-inflammatory cytokine marker levels (MMP9, KC/CXCL1, and IL-1β). MMP9 is implicated in skin blisters and vesicant injuries, and has been shown as a promoter of separation of the epidermis and dermis after skin injuries. HC and A96 treatment reduced
MMP9 levels by 146% and 64%, respectively, compared to vehicle treatment. A96 treatment significantly reduced CXCL1/KC protein levels (47% reduction, p<0.05), whereas HC treatment did not reduce. IL-1β levels were significantly reduced with HC treatment (213% reduction, p<0.05) whereas A96 treatment showed a trend in reduction (Figures 1D-F). Similar to other studied parameters, the tissue extravasation (intensity of IRDye 800 CW dye fluorescence) was significantly reduced with both HC and A96 treatment (p<0.05) (Figure 2). The prominent edematous swelling that was seen in gross punch biopsy samples was evident in the histopathology profiles. Treatment with TRPA1 antagonists reduced edema. Edema reduction with TRPA1 antagonist treatment is also further supported by the reduction in ear thickness and ear punch biopsy weights (Figure 3).

**Chronic inflammation after CS tear gas agent exposure was reduced after treatment with TRPA1 antagonists**

In a 5-day chronic observation study after CS tear gas agent exposure, a profound and chronic inflammation was noted. Ear thickness and ear punch biopsy weights that were used as surrogate markers of edema have significantly increased by 182% and 136%, respectively, with CS exposure. Treatment with either HC or A96 reduced ear thickness (HC, 38% reduction and A96, 42% reduction) and ear punch biopsy weights (HC, 30% reduction and A96, 31% reduction) (p<0.05). While treatment with HC and A96 decreased CXCL2/MIP2 (p<0.05), they showed trends in reduction of KC/CXCL1 and IL-1β (data not shown) (Figure 4). Representative H&E stained histopathological profiles were presented (Figure 5). At the same magnification (20X) of all histopathological profiles, the epidermises on both surfaces of the ears were not visible in the CS+Vehicle group whereas treatment with TRPA1 antagonists decreased edematous swelling. CS exposure also caused epidermal thickening, keratinolysis, and epidermal
desquamation/denudation. Treatment with TRPA1 antagonists partially decreased or did not decrease epidermal thickening. TRPA1 antagonist treatment decreased infiltration of cells and epidermal desquamation.

**Water washing is not an effective decontamination strategy**

Decontamination of CS-exposed mouse ear skin with water washing did not improve the studied parameters such as ear thickness, ear punch biopsy weights, and IL-1β pro-inflammatory cytokine measured in ear punch biopsy homogenate (p>0.05) (Figure S3).

**Activation of TRPA1 ion channels after exposure to CS tear gas agent was inhibited in cells treated with advanced TRPA1 antagonists**

*In vitro* calcium functional assays showed that the human TRPA1 ion channel (EC$_{50}$=0.016 µM; 95% confidence intervals (CI) = 0.01 – 0.024 µM) is highly sensitive to CS tear gas agent compared to the mouse TRPA1 ion channel (EC$_{50}$ = 0.47 µM, 95% CI = 0.32 – 0.83 µM).

Advanced TRPA1 antagonists such as A967079 (mouse IC$_{50}$ = 0.47 µM; human IC$_{50}$ = 23 µM), AMG0902 (mouse IC$_{50}$ = 0.28 µM; human IC$_{50}$ = 0.26 µM) and GDC-0334 (mouse IC$_{50}$ = 0.07 µM; human IC$_{50}$ = 0.095 µM) inhibited CS tear gas agent-induced intracellular calcium influx in a dose-dependent manner (Figure 6).
Discussion

Mouse-ear inflammation models are routinely used for skin toxicity studies (Achanta et al., 2018). The ears of C57BL/6 mice have sparse hair and therefore, are suitable for modeling exposures to human skin. In real riot-control situations, the actual concentration of the exposure to CS tear gas agent is unknown, and is highly variable. Based on our in vitro studies, we found that CS tear gas activates human TRPA1 ion channel at lower concentrations compared to mouse (Mouse: EC$_{50}$ = 0.47 µM; 95% confidence intervals (CI) = 0.32-0.83 µM; Human: EC$_{50}$ = 0.016 µM; 95% CI = 0.01-0.024 µM). The EC$_{50}$ value for activating TRPA1 in mice was 0.47 µM of CS tear gas agent, whereas, in our in vivo mouse model, we exposed to 200 mM of CS tear gas. Our exposure resulted in profound edema, inflammation, and tissue extravasation. Our CS exposure concentrations may have caused saturated skin injuries. Thus, our model represents a severe skin injury phenotype in humans.

In this study, we tested the therapeutic potential of 2 TRPA1 antagonists to mitigate CS-induced skin inflammation. Consistent with in vitro studies published by our laboratory and other investigators, TRPA1 ion channels were shown here to be a key mediator of CS tear gas agent-induced inflammation in skin, based on in vitro calcium functional assays and in vivo mouse studies (Brone et al., 2008; Bessac et al., 2009). TRPA1 antagonists, HC-030031 and A-967079 decreased tissue edema (ear thickness and punch biopsy weights), inflammatory cytokine marker levels, and intensity of IRDye 800CW PEG dye fluorescence in the treated group compared to the vehicle group. Histopathology was improved, particularly edematous swelling, in the treated group compared to the vehicle group. Edema was the prominent feature evidenced by the increase in ear thickness and ear punch biopsy weight measurements, and edematous swelling in histopathology. Treatment with TRPA1 inhibitors significantly reduced edema. Both HC and
A96 have been widely studied in *in vitro* and *in vivo* studies for target engagement studies and various disease indications (Achanta et al., 2018; Achanta and Jordt, 2020; Chen and Terrett, 2020; Talavera et al., 2020; Maglie et al., 2021).

We developed *in vivo* imaging with infra-red fluorescent dye to visualize the extravasation of inflammatory exudate, and to monitor real-time healing. Although such imaging is common in tumor biology studies, this is the first study to use this *in vivo* imaging technique in inflammatory studies (Vasey et al., 1999). Vascular leakage is a common feature of acute inflammation. The non-specific fluorescent dye used in this study, IRDye 800 CW PEG contrast agent (25-60 kDa), reaches the sites of acute inflammation due to vascular leakage, and has a minimal return to the vasculature due to changes in colloid osmotic pressure. The method was optimized to track the progression of inflammation in real-time using these less invasive procedures. In this study, we injected a 1:2 dilution of IRDye 800CW PEG agent (0.5 nmol per animal), which is half the manufacturer’s suggested amount (1 nmol per animal), to avoid signal saturation. Further, since IRDye 800 CW is excreted in the urine, individual caging of mice after injecting the dye is suggested to prevent background noise from urine excreted by cage mates. CS exposure caused profound vascular leakage and treatment with HC or A96 attenuated vascular leakage, suggesting possible tissue integrity and barrier protection.

CS tear gas agent-induced irritation and inflammation effects have been perceived to be transient and acute, with no or minimal toxic effects. However, we showed here that the CS-exposed animals did not recover either rapidly or spontaneously, and that skin exposure to CS caused persistent inflammation and lesions. In the chronic (extended observation) studies, edematous swelling, epidermal thickening, keratinolysis, epidermal desquamation, and infiltration of cells were evident in the control group, whereas improvement was noted in the
TRPA1 antagonist-treated group. In both acute and chronic studies, edematous swelling was very prominent. In chronic studies, at 20X magnification, epidermises on both sides were not visible in the same field of view in the CS+vehicle group due to prominent edematous swelling (Figure 5). In the DMSO group, a single or two-layer epithelial cell layer was present in the epidermis. However, CS exposure resulted in obvious epidermal thickness with multiple layers of epithelial cells. Significant keratinolysis was evident in CS-exposed mice but treatment with TRPA1 antagonists relatively decreased keratinolysis. These findings suggest that therapeutic intervention, or an effective decontamination strategy that is not currently available, is mandatory in cases of exposure to a CS tear gas agent. Here in our study, we exposed mouse ears to one time application of CS. Recent reports suggest that repeated exposure to CS may cause contact dermatitis (Arbak et al., 2014; Lam et al., 2020).

The mice in the treatment group that received HC-030031 following CS tear gas exposure showed decreased activity levels compared to the control group, although this was not objectively quantified. Lower doses of HC and A96 may be effective in reducing CS tear gas agent-induced inflammation; however, our dosing regimen was adopted based on previously published studies (Caceres et al., 2009; Chen et al., 2011; Liu et al., 2016; Achanta et al., 2018; Gyamfi et al., 2020). Nevertheless, both compounds showed decent therapeutic effects in our severe CS skin injury models.

Not only potential medical countermeasures for CS tear gas skin injuries but there are also no approved decontamination strategies for CS tear gas skin exposures. Water washing of the CS tear gas-exposed mouse ears did not resolve inflammation and therefore, may not be an effective decontamination strategy. Water washing coupled with scrubbing with soap might offer additional benefits but we did not investigate in the current study. A couple of decontamination
strategies have been assessed, but not prospectively studied in preclinical studies or humans. RSDL (Emergent BioSolutions, Gaithersburg, MD, USA) is a US FDA-approved emerging product that has been indicated for decontaminating nerve gas exposure. Published in vitro studies show that when RSDL is incubated with CS, the potency of the CS tear gas agent is substantially reduced (Cao et al., 2018; Gebremedhin et al., 2020). However, this has not been confirmed in any preclinical or clinical studies. Diphoterine® (Prevor Laboratory, Valmondois, France) is a commercially available hypertonic, amphoteric, and chelating agent that has shown some benefits in limited human studies but has not yet been studied in preclinical or clinical studies prospectively (Viala et al., 2005; Luka et al., 2007). In our mouse skin exposure studies, decontamination with water did not resolve inflammation. Thus, more definitive studies on decontamination strategies are urgently needed to protect against the effects of CS tear gas exposure in addition to therapeutic interventions.

TRPA1 ion channels are implicated in several inflammatory models, and investigational TRPA1 antagonists are being studied widely for several indications (Bautista et al., 2006; Dai et al., 2007; Macpherson et al., 2007; Bessac and Jordt, 2008; Bessac et al., 2008; Brone et al., 2008; Escalera et al., 2008; Caceres et al., 2009; Bautista et al., 2013; Liu et al., 2013; Radresa et al., 2013; Holzer and Izzo, 2014; Achanta et al., 2018). Expression of TRPA1 is believed to be primarily in the sensory nerve endings of the skin. However, recent studies showed that non-neuronal skin cells such as keratinocytes, melanocytes, mast cells, dendritic cells, and endothelial cells also express TRPA1 (Atoyan et al., 2009; Maglie et al., 2021). These ion channels play an important role in cutaneous physiological functions (Bautista et al., 2013; Maglie et al., 2021). Therefore, pharmacological targeting of TRPA1 ion channels offers a great promise to treat CS tear gas induced skin injuries. Pharmacological inhibition of TRPA1 showed promising results in
other chemical injuries such as sulfur mustard analog-induced skin injuries and many other chemical injuries (Bautista et al., 2006; Stenger et al., 2015; Stenger et al., 2017; Tai et al., 2017; Achanta et al., 2018; Yadav et al., 2023).

While HC-030031, A967079, and other TRPA1 antagonists have been widely tested in several preclinical models with positive outcomes, they also have some off-target effects such as thermoregulation, altered taste and smell, reduced pain perception, chemosensory deficits, etc. The newly discovered TRPA1 antagonists are highly selective and potent with minimal or no side effects. Therefore, there is a need to investigate the newly disclosed TRPA1 antagonists in our CS skin injury models (Table S1). Using in vitro calcium functional assays, we determined the pharmacological activity of advanced TRPA1 antagonists such as AMG0902 and GDC-0334 (Lehto et al., 2016; Schenkel et al., 2016; Balestrini et al., 2021). Both of these compounds effectively inhibited the influx of intracellular calcium ions resulting from CS tear gas-induced activation of TRPA1 ion channels. Consistent with published IC$_{50}$ values for GDC-0334, this antagonist is effective at nanomolar concentrations for inhibiting CS-evoked intracellular calcium influx (Balestrini et al., 2021). In a healthy volunteer Phase 1 study, treatment with GDC-0334 reduced TRPA1 agonist-induced dermal blood flow (DBF), pain, and itch, demonstrating GDC-0334 target engagement in humans. This is the first TRPA1 inhibitor that has exhibited an ideal safety profile and pharmacokinetic parameters (Balestrini et al., 2021). GDC-0334 showed strong therapeutic effects in 4 different preclinical studies (Balestrini et al., 2021). GDC-6599 is a tetrahydrofuran-based TRPA1 inhibitor that showed therapeutic effects against ovalbumin-induced asthma and mustard oil-induced pain model. GDC-6599 exhibited decent safety and pharmacokinetic profile in preclinical models (Terrett et al., 2021). GDC-6599 (Compound 20) entered into a clinical trial study to evaluate the efficacy, safety,
pharmacokinetics, and pharmacodynamic effects in patients with chronic cough (clinical trial number: NCT05660850). Additional TRPA1 antagonists, such as CB-189, CB-625, AP18, GRC-17536 (also known as ISC 17536), BI01305834, and BAY-390 are undergoing active preclinical studies by several pharmaceutical companies (Table S1) (Liu et al., 2013; Skerratt, 2017; Achanta and Jordt, 2020; Chen and Terrett, 2020; van den Berg et al., 2020; Jain et al., 2022; Mesch et al., 2023). Therefore, future studies are warranted to test the therapeutic effects of these latest TRPA1 antagonists in in vivo mouse and non-rodent animal models of CS tear gas exposure.

With the increased and uncontrolled deployment of CS tear gas agents for riot control, casualties are also increasing. In this study, we offer to advance the development of treatments for injuries from exposure to CS tear gas agent based on mechanistic studies.

Conclusions
We demonstrated that the TRPA1 ion channel as a key mediator of tear gas-induced inflammation and TRPA1 antagonists, such as HC-030031 and A-967079 decreased tissue edema, inflammatory cytokine markers, and vascular extravasation in CS tear gas-induced skin injuries while improving tissue histopathology. These findings will pave the way for studying advanced TRPA1 inhibitors in rodent and non-rodent species for treating human CS tear gas-induced skin injuries under FDA’s animal rule as potential therapeutic agents.
Acknowledgments

The authors would like to thank Dr. Sairam V Jabba, Ph.D., Research Scientist, Duke University School of Medicine, for his thoughtful discussions on in vitro calcium functional assay; Hydra Biosciences LLC (Cambridge, MA, USA) and Genentech (South San Francisco, CA, USA) for the generous gift of HC-030031 and GDC-0334, respectively.

Conflict of interests

S.-E.J served on the scientific advisory board of Hydra Biosciences LLC (Cambridge, MA), a biopharmaceutical firm developing TRP ion channel inhibitors for the treatment of pain.

Data Availability Statement

The authors declare that all the data that support the findings of this study are available within the paper and its Supplemental Data.

Authorship Contributions.

Participated in research design: Achanta, S; Chintagari, N; Jordt, S.
Conducted experiments: Achanta, S; Chintagari N; Balakrishna, S; Boyi, S;
Contributed new reagents or analytic tools: Achanta, S; Chintagari N; Balakrishna, S; Boyi, S; Jordt, S
Performed data analysis: Achanta, S; Chintagari, N; Balakrishna, S
Wrote or contributed to the writing of the manuscript: Achanta, S; Balakrishna, S
References

Aktan AO (2013) Tear gas is a chemical weapon, and Turkey should not use it to torture civilians. BMJ 346:f3801.


Davenport K (2020) Tear Gas is Banned in War. It is Time to Ban its Domestic Use., in, Washington, DC.


Martin D (2022) Tear gas video triggers investigation into Navy SEAL selection course, in.


Footnotes

Some elements of this work has been submitted as an abstract to the Society of Toxicology annual meeting, Phoenix, AZ. S Achanta won the “Stratacor Postdoctoral Award”, presented by the Dermal Toxicology specialty section, Society of Toxicology.

S.A. and S.-E.J are supported by the NIH Countermeasures Against Chemical Threats (CounterACT) Program – National Institutes of Environmental Health Sciences (NIEHS) [U01ES030672; 1R21-ES033020; R01ES034387]. The content is solely the responsibility of the author and does not necessarily represent the views of the NIH or the FDA.

Disclaimer: Dr. Chintagari contributed to this work when he was at Yale University School of Medicine, New Haven, CT
Figure legends

Figure 1. Effects of TRPA1 antagonists on CS tear gas agent-induced cutaneous inflammation. (A) CS tear gas exposure and treatment paradigm. The right ears of C57BL/6 male mice were exposed to CS (200 mM, 20 µL) and the left ears to DMSO (solvent for CS, 20 µL). At 0.5 and 4 hours post-CS exposure, mice were treated with vehicle (0.5% methylcellulose), HC-030031 (HC), or A967079 (A96) intraperitoneally (i.p). At 4 hours post-CS exposure, mice were injected with IRDye 800CW contrast agent intravenously (i.v), and in vivo imaging was performed at 5.5 hours post-CS exposure. At 6.5 hours post-CS exposure, mice were euthanized, ear thickness was measured, and ear punch biopsies were collected. (B-F) Ear thickness, ear punch biopsy weights, and pro-inflammatory cytokine markers in mice exposed to CS tear gas agent and received either vehicle (0.5% methylcellulose) or TRPA1 antagonist (HC or A96). Data were analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison test. Data are presented as mean ± SEM, n=5 per group. * p≤0.05, ** p≤0.01, *** p≤0.001, ns = non-significant.

Figure 2. Effect of TRPA1 antagonists on decreasing CS tear gas agent-induced cutaneous vascular leakage. The right ears of C57BL/6 male mice were exposed to CS (200 mM, 20 µL) and the left ears to DMSO (solvent for CS, 20 µL). At 0.5 and 4 hours post-CS exposure, mice were treated with vehicle (0.5% methylcellulose), HC-030031 (HC), or A967079 (A96) intraperitoneally (i.p). At 4 hours post-CS exposure, mice were injected with IRDye 800CW contrast agent intravenously (i.v) and in vivo imaging was performed at 5.5 hours post-CS exposure using MousePod fitted on Li-COR Odyssey CLX. Representative scan profiles of mice showing profound vascular leakage in the control group (A) and decreased vascular leakage in the treated groups (B-C). Photograph showing MousePod™ fitted with Li-COR Odyssey CLX.
(D). Bar graph showing the quantification of IRDye 800CW contrast agent that leaked into the ear subcutaneous tissue (E). Data were analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison test. Data are presented as mean ± SEM, n=3-4 per group. * p≤0.05.

Figure 3. Effects of TRPA1 antagonists on CS tear gas agent-induced histopathology features. Right ears of C57BL/6 male mice were exposed to CS (200 mM, 20 µL), and left ears to DMSO (solvent for CS, 20 µL). At 0.5 and 4 hours post-CS exposure, mice were treated with vehicle (0.5% methylcellulose), HC-030031 (HC), or A967079 (A96) intraperitoneally (i.p). At 6.5 hours post-CS exposure, mice were euthanized, and ear punch biopsies were collected for histopathological analysis. Representative H&E stained histopathologic sections from DMSO (solvent for CS), CS+vehicle, CS+HC030031, and CS+A967079 groups are presented at 20X magnification. e = epidermis; d = dermis; hf = hair follicle; ec = elastic cartilage; black arrow heads = infiltration of leucocytes.

Figure 4. Persistent skin injuries after CS tear gas agent exposure, and effects of TRPA1 antagonists on skin inflammation in an extended mouse observation model. (A) CS tear gas exposure and treatment. Right ears of C57BL/6 male mice were exposed to CS (200 mM, 20 µL), and left ears to DMSO (solvent for CS, 20 µL). At 0.5, 4, 24, and 48 hours post-CS exposure, mice were treated with vehicle (0.5% methylcellulose), HC-030031 (HC), or A967079 (A96) intraperitoneally (i.p). B-E) Ear thickness, ear punch biopsy weights, and cytokine markers in mice receiving vehicle or TRPA1 antagonist after exposure to CS tear gas agent. Data were analyzed by one-way ANOVA with Tukey’s post-hoc multiple comparison test. Data
are presented as mean ± SEM, n=5 per group. * p≤0.05, ** p≤0.01, *** p≤0.001, ns = non-significant.

Figure 5. Histological images of skin injuries after CS tear gas agent exposure and treatment with TRPA1 antagonists. Right ears of C57BL/6 male mice were exposed to CS (200 mM, 20 µL) and left ears to DMSO (solvent for CS, 20 µL). At 0.5, 4, 24, and 48 hours post-CS exposure, mice were treated with vehicle (0.5% methylcellulose), HC-030031 (HC), or A967079 (A96) intraperitoneally (i.p). Representative H&E stained histopathologic sections from DMSO, CS+vehicle, CS+HC-030031, and CS+A967079 groups are presented at 20X magnification. e = epidermis; d = dermis; hf = hair follicle; ec = elastic cartilage; black arrow heads = infiltration of leucocytes; red arrow = epidermal thickening.

Figure 6. Effects of advanced TRPA1 antagonists on CS tear gas agent-induced calcium influx. HEK293T cells were transfected with mouse (A-B) and human (C-D) TRPA1 plasmid. A and C. Show dose-response curve of CS tear gas (Mouse: EC$_{50}$ = 0.47 µM; 95% confidence intervals (CI) = 0.32-0.83 µM; Human: EC$_{50}$ = 0.016 µM; 95% CI = 0.01-0.024 µM). B and D. TRPA1 antagonists (A967079 (A96), AMG0902; or GDC0334) inhibited the calcium influx response elicited by CS tear gas in mouse and human TRPA1-transfected cells. IC$_{50}$ and 95% CI values are presented in tables under figures 6B and 6D. Data is presented as mean ± SEM. Each experiment was performed with a minimum of 3 replicates.
Figure 1

A

C57BL/6 mice (8-9 week, 20-30 g)

1 week acclimation

20 μL of CS (200 mM) on right ear; DMSO on left ear

HC-030031 or A967079 200 mg/kg i.p

0 hr 0.5 hr 2 hr 4 hr 5.5 hr 6.5 hr

HC-030031 or A967079 100 mg/kg i.p

In vivo imaging

IRDye 800CW PEG contrast agent i.v

B

Ear thickness

% over control

CS+Veh CS+HC CS+A96

C

Ear punch biopsy weights

% over control

CS+Veh CS+HC CS+A96

D

MMP9

ng/mg of protein

Control CS+Veh CS+HC CS+A96

E

CXCL1/KC

pg/mg of protein

Control CS+Veh CS+HC CS+A96

F

IL-1β

pg/μg of protein

Control CS+Veh CS+HC CS+A96

* * * ns * *
Figure 4

A

C57BL/6 mice (8-9 week, 20-30 g)

20 μL of CS (200 mM) on right ear; DMSO on left ear

1 week acclimation

HC-030031 or A967079, 200 mg/kg i.p

HC-030031 or A967079, 100 mg/kg i.p

Euthanasia, ear thickness measurement, and ear punch biopsy collection

B

C

D

E

Ear thickness

Ear punch biopsy weights

KC/CXCL1

CXCL2/MIP-2

% over control

% over control

pg/mg of protein

pg/mg of protein

Control CS+Veh CS+HC CS+A96

Control CS+Veh CS+HC CS+A96

* ** ns **** *
Figure 6

(A) mTRPA1: CS

EC$_{50}$ = 0.47 µM
(95% CI = 0.32 - 0.83)

(B) mTRPA1: CS+TRPA1 antagonist

<table>
<thead>
<tr>
<th></th>
<th>A967079</th>
<th>AM0902</th>
<th>GDC0334</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC$_{50}$ (µM)</td>
<td>0.47</td>
<td>0.28</td>
<td>0.07</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.27 - 0.82</td>
<td>0.17 - 0.49</td>
<td>0.05 - 0.98</td>
</tr>
</tbody>
</table>

(C) hTRPA1: CS

EC$_{50}$ = 0.016 µM
(95% CI = 0.01 - 0.024)

(D) hTRPA1: CS+TRPA1 antagonist

<table>
<thead>
<tr>
<th></th>
<th>A967079</th>
<th>AM0902</th>
<th>GDC0334</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC$_{50}$ (µM)</td>
<td>23</td>
<td>0.26</td>
<td>0.095</td>
</tr>
<tr>
<td>95% CI</td>
<td>6.1 - 86</td>
<td>0.22 - 0.31</td>
<td>0.07 - 0.12</td>
</tr>
</tbody>
</table>